SABCS 2021
Good data with further questions for future treatment in a neoadjuvant setting
KEYNOTE-522
SABCS 2021
Good data with further questions for future treatment…
KeyNOTE-522
SABCS 2021
Re-evaluation confirms old data
RxPONDER
SABCS 2021
Benefit only related to chemotherapy?!
CCtG MA.32 (Metformin)
SABCS 2021
Metformin shows no efficacy for most cancer patients
KEYRICHED-1
SABCS 2021
Hypothesis-generating study in the HER2-enriched…
BRE12-158
SABCS 2021
Molecular-guided treatment is of value in combination…
TEXT, SOFT
SABCS 2021
The risk-adapted decision for or against AI has to be…
CCtGMA.32 (Metformin)
SABCS 2021
Metformin is not an anti-cancer drug
Breast Pre-Cancer Atlas
SABCS 2021
Genomic signatures of DCIS
RXPONDER
SABCS 2021
Critical consideration of the study data is necessary
RXPonder; CCtGMA.32 (Metformin)
SABCS 2021
Solved and unsolved controversies of early breast…
PALLAS
SABCS 2021
Negative results with hope for translational projects
cTRAK TN
SABCS 2021
Leading the way for other ct-DNA trials
Keynote-522
SABCS 2021
The next standard for TNBC?!
Breast Pre-Cancer Atlas
SABCS 2021
"Signatures Genomiche " nel carcinoma duttale in situ
Bre12-158
SABCS 2021
Genomisch gesteuererte Therapie sinnvoll in Kombi mit…
RxPONDER
SABCS 2021
E’ solo effetto della chemioterapia?
KEYRICHED-1
SABCS 2021
Hypothesen-generierende Studie beim HER2-enriched…
TEXT, SOFT
SABCS 2021
Muss die risiko-adaptierte Entscheidungsfindung bei AI…
CCtGMA.32 (Metformin)
SABCS 2021
La metformina non può essere considerata un farmaco…
KeyNOTE-522
SABCS 2021
Erneute Auswertung bestätigt alte Daten
RXPONDER
SABCS 2021
Kritische Betrachtung der Studiendaten notwendig
PALLAS
SABCS 2021
Negative Ergebnisse, aber Hoffnung für translationale…
Keynote-522; OlympiA
SABCS 2021
KEYNOTE-522 confirms ICI benefit in the neoadjuvant…
RxPONDER
SABCS 2021
RxPONDER: Benefit only for pre-menopausal patients?…
cTRAK TN
SABCS 2021
cTRAK TN: ctDNA monitoring not yet ready for primetime.…
Destiny-Breast 03; DAISY; SUMMIT
SABCS 2021
HER2+ EBC: Chemotherapy free regimens? Extended…
Keynote-522
SABCS 2021
TNBC EBC: What is the new neoadjuvant standard…
PALLAS; PENELOPE-B
SABCS 2021
HR+ EBC: What about PALLAS/PENELOPE-B? What is the…
SABCS 2021
MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…
MSK IMPACT
SABCS 2021
Patients with BRCA2 don't show PFS benefit with CDK4/6i
DESTINY Breast-03
SABCS 2021
TDXd is very efficient in patients with brain…
Destiny-Breast03
SABCS 2021
T-Dxd is also active in patients with brain metastasis
SAFIR02-Breast
SABCS 2021
Pioneering study of personalized medicine in advanced…
NIMBUS
SABCS 2021
Immuntherapy for high tumor mutation burden in…
Pada-1
SABCS 2021
PFS improvement with fulvestrant in patients with…
SABCS 2021
Best of the year: systemic therapy
EMERALD
SABCS 2021
Oral SERDs are efficient, but show high progression…
SAFIR02-Breast
SABCS 2021
Precision oncology is beneficial in certain mBC…
Keynote-355; Tropion-PanTumor01
SABCS 2021
Exciting novel therapies for metastatic TNBC
EMERALD
SABCS 2021
Oral SERDs for early setting and adjuvant therapy
DAISY
SABCS 2021
Activity of T-Dxd across all Her2-expressing breast…
EMERALD
SABCS 2021
Very good news for endocrine resistant metastatic…
Samuraciclib Phase I
SABCS 2021
Samuraciclib - new targeted therapy for luminal breast…
TROPION-PanTumor01; ASCENT
SABCS 2021
TROP2 - new target for improved chemotherapy
Pada-1
SABCS 2021
Switching with molecular progress improves PFS
EMERALD
SABCS 2021
Elacestrant - less than we expected
KeyNOTE-522
SABCS 2021
Robust benefit of pembroluzimab in addition to…
Tropion-PanTumor01
SABCS 2021
Promising results for TNBC patients
Nimbus; Keynote-355
SABCS 2021
Chekpoint inhibition in breast cancer
Nimbus
SABCS 2021
IO + IO without resounding success in the mBC setting
Destiny-Breast03; DAISY
SABCS 2021
More good news for TDXd
NeoTRIPaPDL1
ASH 2021
Imaging with mass cytometry can provide predictive…
KeyNOTE-355
SABCS 2021
Effectiveness depending on PDL1 status
KEYNOT-355
SABCS 2021
Which patients will benefit from Pembro in metastatic…
SABCS 2021
My highlights of 2021 in metastatic breast cancer
MONALEESA 2, 3, 7
SABCS 2021
Pooled analyses shows OS benefit for most subgroups
Tropion-PanTumor01
SABCS 2021
Dato-DXd new promising ADC
Keynote-522 Keynote-355 Destiny-Breast03
SABCS 2021
3 updates - 3 new standards of care
Tropion-PanTumor01
SBCS 2021
Dato-Dxd for metastatic TNBC
SABCS 2021
Amazing period for patients with refractory metastatic…
Keynote-355
SABCS 2021
Final results of the CPS score subgroup analyses show…
Destiny-Breast03; DAISY
SABCS 2021
Reconfirming effect of T-DXd in patients with brain…
Emerald
SABCS 2021
Werden orale SERDs die Therapie mit Fulvestrant in…
Nimbus
SABCS 2021
IO + IO ohne durchschlagenden Erfolg beim mBC
Pada-1
SABCS 2021
Amélioration de la survie sans progression par le…
SABCS 2021
Mi retrospectiva del cáncer de mama metastático en 2021
SAFIR02-BREAST
SABCS 2021
Präzisionsonkologie funktioniert beim mBC
Monaleesa 2, 3, 7
SABCS 2021
Gepoolte Analyse zeigt OS Vorteil für fast alle…
KeyNOTE-355
SABCS 2021
Wirksamkeit in Abhängigkeit von PDL1-Stautus
Tropion-PanTumor01
SABCS 2021
Résultats prometteurs dans le cancer du sein triple…
Safir02-Breast
SABCS 2021
Wegweisende Daten für die personalisierte Medizin beim…
Keynote-355
SABCS 2021
Resultados finales de los análisis de los subgrupos de…
Tropion-PanTumor01
SABCS 2021
È un grande momento per i pazienti con tumore mammario…
Samuraciclib Phase I
SABCS 2021
Samuracyklib – nowe leczenie celowane w rakach…
Destiny-Breast-03
SABCS 2021
TDXd zeigt große Wirksamkeit bei Hirnmetastasen
Destiny-Breast03
SABCS 2021
Activité du T-DXd dans les metastases cérébrales
Emerald
SABCS 2021
Buone notizie per i tumori mammari endocrino resistenti
Emerald
SABCS 2021
Oraler Serd wirkt, aber hohe Rate an primärer Resistenz
Keynote-522
SABCS 2021
Important benefice de l’ajout du pembrolizumab à la…
Tropion-PanTumor01; Ascent
SABCS 2021
Neues Target für optimierte Chemotherapie
MSK Impact
SABCS 2021
HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…
SABCS 2021
Best of the Year: Systemtherapie
Nimbus; Keynote-355
SABCS 2021
Checkpoint-Inhibition beim Mammakarzinom
PADA-1
SABCS 2021
Umstellung bei molekularem Progress verlängert PFS
Destiny-Breast03
SABCS 2021
T-Dxd aktywny również w przerzutach do mózgu
Emerald
SABCS 2021
Elacestrant – poniżej oczekiwań
NeoTRIPaPDL1
SABCS 2021
L’imaging mass cytometry può aiutare a predire…
Tropion-PanTumor01
SABCS 2021
Dato-DXd – nowy obiecujący koniugat przeciwciała i…
Tropion-PanTumor01
SABCS 2021
Risultati promettenti nel tumore al seno triplo…
SABCS 2021
MBC HER2+: How can we manage the metastatic disease and…
SABCS 2021
MBC TNBC: Molecular tumor characteristics define the…
SABCS 2021
MBC HR+: What is the best option after a CDK4/6i…
SABCS 2021
Integrating patients perspectives in metastatic breast…
Keynote-355
SABCS 2021
Treatment options for patients with metastatic TNBC
SUMMIT
SABCS 2021
Targeting rare mutations in breast cancer - is this the…
EMERALD
SABCS 2021
Are SERDs a future therapy for endocrine resistant…
TROPION-Tumor01
SABCS 2021
New ADCs on the horizon for TNBC patients
Destiny-Breast03
SABCS 2021
Therapy of brain metastasis – can T-DXd be the new SoC?
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!